Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of trilaciclib for prevention of chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer
CTR20210562Phase 3Active
- Sponsor
- G1 Therapeutics, Inc.
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trilaciclib in myelosuppression, sponsored by G1 Therapeutics, Inc.. Started May 2021; status: active.
02
Drugs
trilaciclib
03
Conditions
myelosuppression
Beyond the preview
Go deeper on CTR20210562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210562.